- $41.45m
- $29.09m
- $1.12m
Australia's Imugene hits 1-1/2-month high on collaboration with RenovoRx
U.S. STOCKS ON THE MOVE-Micron, Greenbrier, Immunome
RenovoRx rises on positive data from pancreatic cancer therapy study
U.S. STOCKS ON THE MOVE-Sigilon, Netflix, RenovoRx
RenovoRx rises on positive data from pancreatic cancer therapy study
Brief: Renovorx Announces New Positive Interim Late-Stage Data For Cancer Treatment
Brief: RenovoRx Appoints Margaret Tempero To Scientific Advisory Board
Brief: Renovorx Initiates Patient Enrollment At University Of Texas Southwestern Medical Center For Pivotal Phase Iii Tiger-Pac Clinical Trial
Brief: Renovorx Reports First Quarter 2023 Financial Results And Operational Highlights
Brief: RenovoRx Appoints Robert Spiegel To Board Of Directors
Brief: Renovorx Presenting Phase Iii Trial Interim Analysis Data At American Association For Cancer Research Annual Meeting In Florida
RenovoRx rises on positive late-stage trial data for pancreatic cancer therapy
Brief: RenovoRx Announces Positive New Data From Phase III Clinical Trial Interim Analysis
Brief: RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data
Brief: Renovorx Reports Full Year 2022 Financial Results And Achievement Of Important Phase III Clinical Study Milestone
Brief: RenovoRx Announces Initial Results In Pharmacokinetic Substudy
Brief: RenovoRx Strengthens IP Portfolio With Eighth U.S. Patent
Brief: Renovorx Reports Third Quarter 2022 Financial Results
Brief: Renovorx Inc Files For Mixed Shelf Of Up To $50 Mln - SEC Filing